FIELD: medicine.
SUBSTANCE: present invention relates to the field of phage therapy and to a composition and use thereof. Present composition comprises: a first and second purified bacteriophage strains, each of said strains having a genome characterized by at least 99% sequence identity to the corresponding nucleic acid sequence, selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, showing antibacterial activity against Staphylococcus aureus; third and fourth purified bacteriophage strains having a genome characterized by at least 99% sequence identity to the nucleic acid sequences SEQ ID NO:3 and SEQ ID NO:4, respectively, showing antibacterial activity against Pseudomonas aeruginosa; and a fifth purified bacteriophage strain having a genome characterized by at least 99% sequence identity to the nucleic acid sequence SEQ ID NO:5 showing antibacterial activity against Acinetobacter baumannii. Each of said first, second, fourth and fifth bacteriophage strains is present in the composition in an amount corresponding to about 10 times that of the third bacteriophage strain. Present method comprises administering to a subject a therapeutically effective amount of said composition.
EFFECT: inventions can be used for the treatment and control of bacterial infections, caused by one or more of Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii, in particular diabetic foot infections.
25 cl, 14 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BACTERIOPHAGES, PHAGE PEPTIDES AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2614114C2 |
| ANTIBACTERIAL COMPOSITION FOR PREVENTION OR TREATMENT OF HOSPITAL INFECTIONS (VERSIONS), BACTERIOPHAGE STAMPS USED TO OBTAIN SUCH COMPOSITION | 2015 |
|
RU2628312C2 |
| BACTERIOPHAGES, PROTEINS OF BACTERIOPHAGES AND METHODS FOR USE THEREOF | 2014 |
|
RU2671110C2 |
| BACTERIOPHAGE POSSESSING ANTI-PSEUDOMONAS AERUGINOSA ACTIVITY, BACTERIOPHAGE PROTEINS AND METHODS FOR USING THEM | 2010 |
|
RU2580248C9 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST BACTERIA PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI, SALMONELLA TYPHI AND STAPHYLOCOCCUS HAEMOLYTICUS (EMBODIMENTS) | 2019 |
|
RU2730613C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST BACTERIA PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI, SALMONELLA TYPHI AND STAPHYLOCOCCUS HAEMOLYTICUS (EMBODIMENTS) | 2019 |
|
RU2730614C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST GRAM-NEGATIVE BACTERIA: PSEUDOMONAS AERUGINOSA, ACINETOBACTER BAUMANNII, KLEBSIELLA PNEUMONIAE AND SALMONELLA TYPHI (EMBODIMENTS) | 2019 |
|
RU2730615C1 |
| ACINETOBACTER LYSINES | 2015 |
|
RU2725809C2 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS AN ANTIMICROBIAL AGENT DIRECTED AGAINST ACINETOBACTER BAUMANNII BACTERIA, (EMBODIMENTS) | 2019 |
|
RU2730616C1 |
| METHOD FOR THE TREATMENT AND PREVENTION OF RECURRENCE OF NOSOCOMIAL PNEUMONIA | 2021 |
|
RU2794585C2 |
